Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28694398 | 0.97 | CA12 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL26882982 | 0.89 | KDM4E (0.60) | KDM4EALDH1A1HPGDNPSR1GAA | |
| SCHEMBL829753 | 0.88 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29438041 | 0.85 | KDM4E (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL68218 | 0.85 | KDM4E (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18952948 | 0.85 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9480503 | 0.84 | CFTR (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10479344 | 0.83 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17922667 | 0.83 | CYP2A6 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30151494 | 0.83 | PTPN11 (0.58) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4089453-A | — | — | None | — | — | JP | disclosed |
| US-9676686-B2 | Liquid crystal composition containing nitrogen-containing cyclic compound and liquid crystal display device | JNC CORPORATION (JP) | 2017-06-13 | — | — | US | disclosed |
| US-9631142-B2 | Piperidine derivative, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-04-25 | — | — | US | disclosed |
| US-20160208172-A1 | LIQUID CRYSTAL COMPOSITION CONTAINING NITROGEN-CONTAINING CYCLIC COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-07-21 | — | — | US | disclosed |
| US-20160090534-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-03-31 | — | — | US | disclosed |
| JP-H0489453-A | SEPARATION AND PURIFICATION OF TETRACARBOXYLIC ACID | NKK CORP | 1992-03-23 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090534-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | MBD2, SSB, MBTD1 | CA12 3265/4885CA1 725/4885CA2 2140/4885 |
| US-20160208172-A1 | LIQUID CRYSTAL COMPOSITION CONTAINING NITROGEN-CONTAINING CYCLIC COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE | CCND2, ROCK2, CCND1 | CA12 1249/4885CA1 953/4885CA2 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.